


Primary Endpoint
Placebo
Dapagliflozin
Cumulative Percentage (%)
0
10
20
30
40
50
0
3
6
9
12
15
18
21
24
Months since Randomization
Number at Risk
Dapagliflozin 2373 2305 2221 2147 2002 1560 1146 612 210
Placebo 2371 2258 2163 2075 1917 1478 1096 593 210
Dapagliflozin
Placebo

Fig. 1


2A
Primary Endpoint
Cumulative Percentage (%)
0
10
20
30
40
50
Placebo
Dapagliflozin
0 3 6 9 12 15 18 21 24
Months since Randomization
Number at Risk
Dapagliflozin 2373 2305 2221 2147 2002 1560 1146 612 210
Placebo 2371 2258 2163 2075 1917 1478 1096 593 210
Dapagliflozin
Placebo
2B
Hospitalization for Heart Failure
Cumulative Percentage (%)
0
10
20
30
40
50
Placebo
Dapagliflozin
0 3 6 9 12 15 18 21 24
Months since Randomization
Number at Risk
Dapagliflozin 2373 2306 2223 2153 2007 1563 1147 613 210
Placebo 2371 2264 2168 2082 1924 1483 1101 596 212
Dapagliflozin
Placebo
2C
Death from Cardiovascular Causes
Cumulative Percentage (%)
0
10
20
30
40
50
Placebo
Dapagliflozin
0 3 6 9 12 15 18 21 24
Months since Randomization
Number at Risk
Dapagliflozin 2373 2339 2293 2248 2127 1664 1242 671 232
Placebo 2371 2330 2279 2230 2091 1636 1219 664 234
Dapagliflozin
Placebo
2D
Death from Any Cause
Cumulative Percentage (%)
0
10
20
30
40
50
Placebo
Dapagliflozin
0 3 6 9 12 15 18 21 24
Months since Randomization
Number at Risk
Dapagliflozin 2373 2342 2296 2251 2130 1666 1243 672 233
Placebo 2371 2330 2279 2231 2092 1638 1221 665 235
Dapagliflozin
Placebo

Figs. 2A-2D

Outcome
Dapagliflozin 10mg (n=2373)
Placebo (n=2371)
HR (95% CI)
P value
Cardiovascular death, hospitalization for heart failure or urgent heart failure visit
386 (16 3)
502 (21.2)
0.74 (0.65, 0.85)
<0.001
Hospitalization for heart failure or urgent heart failure visit
237 (10.0)
326 (13 7)
0.70 (0.59, 0.83)
<0.001
Hospitalization for heart failure
231 (9.7)
318 (13.4)
0.70 (0.59, 0.83)
<0 001
Urgent heart failure visit
10 (0.4)
23 (1 0)
0.43 (0.20, 0.90)
0 02
Cardiovascular death
227 (9.6)
273 (11.5)
0.82 (0 69, 0.98)
0.03
Cardiovascular death or hospitalization for heart failure
382 (16.1)
495 (20.9)
0.75 (0.65, 0 85)
<0.001
Death from any cause
276 (11.6)
329 (13.9)
0.83 (0.71, 0.97)
.4
.8
1
1.2
Dapagliflozin 10mg Better
Placebo Better

Fig. 3



Characteristics
Dapagliflozin 10mg (n=2373)
Placebo (n=2371)
HR (95% CI)
Overall Effect 386/2373 502/2371 0.74 (0.65, 0.85)
Age (years)
≤65 162/1032 196/998 0.78 (0.63, 0.96)
>65 224/1341 306/1373 0.72 (0.60, 0.85)
Sex
Male 307/1809 406/1826 0.73 (0.63, 0.85)
Female 79/564 96/545 0.79 (0.59, 1.06)
Race
White 275/1662 348/1671 0.78 (0.66, 0.91)
Black or African 26/122 32/104 0.62 (0.37, 1.04)
Asian 78/552 118/564 0.64 (0.48, 0.86)
Other 7/37 4/32
Geographic Region
Asia 77/543 114/553 0.65 (0.49, 0.87)
Europe 193/1094 218/1060 0.84 (0.69, 1.01)
North America 54/335 73/342 0.73 (0.51, 1.03)
South America 62/401 97/416 0.64 (0.47, 0.88)
NYHA class
II 190/1606 289/1597 0.63 (0.52, 0.75)
III or IV 196/767 213/774 0.90 (0.74, 1.09)
LVEF
≤ Median 222/1230 307/1239 0.70 (0.59, 0.84)
> Median 164/1143 195/1132 0.81 (0.65, 0.99)
NT-proBNP
≤ Median 100/1193 155/1179 0.63 (0.49, 0.80)
> Median 286/1179 347/1191 0.79 (0.68, 0.92)
Prior hospitalization for HF
Yes 195/1124 279/1127 0.67 (0.56, 0.80)
No 191/1249 223/1244 0.84 (0.69, 1.01)
MRA at baseline
Yes 281/1696 361/1674 0.74 (0.63, 0.87)
No 105/677 141/697 0.74 (0.57, 0.95)
Type 2 diabetes at baseline
Yes 215/1075 271/1064 0.75 (0.63, 0.90)
No 171/1298 231/1307 0.73 (0.60, 0.88)
Atrial fibrilation or flutter at enrolment ECG
Yes 109/569 126/559 0.82 (0.63, 1.06)
No 277/1804 376/1812 0.72 (0.61, 0.84)
Main Etiology of HF
Ischemic 223/1316 289/1358 0.77 (0.65, 0.92)
Non-Ischemic/Unknown 163/1057 213/1013 0.71 (0.58, 0.87)
BMI(kg/m2)
< 30 259/1537 320/1533 0.78 (0.66, 0.92)
≥ 30 127/834 182/838 0.69 (0.55, 0.86)
Baseline eGFR (ml/min/1.73m2)
< 60 191/962 254/964 0.72 (0.59, 0.86)
≥60 195/1410 248/1406 0.76 (0.63, 0.92)
.5
.8
1
1.25
2
Dapagliflozin 10mg Better
Placebo Better

Fig. 4



Primary Composite Endpoint
KCCQ TSS ≤ 65.6
KCCQ TSS 65.7-87.5
KCCQ TSS > 87.5
Cumulative Percentage (%)
100
80
60
40
20
0
0
3
6
9
12
15
18
21
24
Months since Randomization
Number at Risk
KCCQ TSS≤ 65.6 1487 1395 1306 1247 1152 934 697 380 140
KCCQ TSS 65.7-87.5 1564 1512 1469 1410 1302 1022 785 431 153
KCCQ TSS > 87.5 1392 1365 1331 1300 1214 925 652 341 116

FIG. 5

Outcome	Dapagliflozin	Placebo	HR (95% CI)	p-value
Cardiovascular Death, Hospitalization for Heart Failure or Urgent Heart Failure Visit				0.52
≤65.6 (n=1487)	162/768	209/719	0.70 (0.57, 0.86)	
65.7-87.5 (n=1564)	119/773	152/791	0.77 (0.61, 0.98)	
>87.5 (n=1392)	73/693	116/699	0.62 (0.46, 0.83)	
Cardiovascular Death or Hospitalization for Heart Failure				0.53
≤65.6 (n=1487)	160/768	205/719	0.71 (0.57, 0.87)	
65.7-87.5 (n=1564)	118/773	150/791	0.77 (0.61, 0.99)	
>87.5 (n=1392)	73/693	115/699	0.62 (0.46, 0.83)	
Hospitalization for Heart Failure or Urgent Heart Failure Visit				0.38
≤65.6 (n=1487)	99/768	134/719	0.67 (0.51, 0.86)	
65.7-87.5 (n=1564)	78/773	101/791	0.76 (0.56, 1.02)	
>87.5 (n=1392)	43/693	78/699	0.54 (0.37, 0.78)	
Hospitalization for Heart Failure				0.40
≤65.6 (n=1487)	96/768	130/719	0.67 (0.51, 0.87)	
65.7-87.5 (n=1564)	76/773	98/791	0.76 (0.56, 1.03)	
>87.5 (n=1392)	43/693	77/699	0.55 (0.38, 0.79)	
Cardiovascular Death				0.82
≤65.6 (n=1487)	107/768	121/719	0.84 (0.64, 1.09)	
65.7-87.5 (n=1564)	63/773	81/791	0.78 (0.56, 1.09)	
>87.5 (n=1392)	39/693	54/699	0.72 (0.48, 1.09)	
Death from Any Cause				0.45
≤65.6 (n=1487)	134/768	142/719	0.89 (0.70, 1.13)	
65.7-87.5 (n=1564)	76/773	99/791	0.77 (0.57, 1.04)	
>87.5 (n=1392)	46/693	67/699	0.68 (0.47, 0.99)	




FIG. 6

Fig. 7A KCCQ Total Symptom Score




FIG. 7B KCCQ Clinical Summary Score




FIG. 7C KCCQ Overall Summary Score




FIG. 8A KCCQ Total Symptom Score




FIG. 8B KCCQ Total Symptom Score




FIG. 8C KCCQ Clinical Summary Score




FIG. 8D KCCQ Clinical Summary Score




FIG. 8E KCCQ Overall Summary Score




FIG. 8F KCCQ Overall Summary Score





FIG. 9
Primary composite endpoint, hospital admission for worsening heart failure, death from cardiovascular causes and death from all causes, according to diabetes status at baseline




Number at Risk

No T2DM/Dapagliflozin	1298	1268	1227	1192	1126	882	646	353	122
No T2DM/Placebo	1307	1253	1214	1176	1101	848	627	340	121
T2DM/Dapagliflozin	1075	1037	994	955	876	678	500	259	88
T2DM/Placebo	1064	1005	949	899	816	630	469	253	89

------- No T2DM/Dapagliflozin ····· No T2DM/Placebo
——— T2DM/Dapagliflozin ——— T2DM/Placebo

FIG. 9A



Number at Risk

No T2DM/Dapagliflozin	1298	1268	1227	1194	1128	882	646	353	122
No T2DM/Placebo	1307	1255	1217	1181	1105	851	631	342	122
T2DM/Dapagliflozin	1075	1038	996	959	879	681	501	260	88
T2DM/Placebo	1064	1009	951	901	819	632	470	254	90

------- No T2DM/Dapagliflozin ····· No T2DM/Placebo
——— T2DM/Dapagliflozin ——— T2DM/Placebo

FIG. 9B



Death from cardiovascular causes
Cumulative Percentage (%)
35
30
25
20
15
10
5
0
0 3 6 9 12 15 18 21 24
Months since Randomization
T2DM/Placebo
T2DM/Dapa
No T2DM/Placebo
No T2DM/Dapa
Number at Risk
No T2DM/Dapagliflozin 1298 1268 1227 1192 1126 882 646 353 122
No T2DM/Placebo 1307 1253 1214 1176 1101 848 627 340 121
T2DM/Dapagliflozin 1075 1037 994 955 876 678 500 259 88
T2DM/Placebo 1064 1005 949 899 816 630 469 253 89
No T2DM/Dapagliflozin
No T2DM/Placebo
T2DM/Dapagliflozin
T2DM/Placebo

FIG. 9C



Death from all causes
Cumulative Percentage (%)
35
30
25
20
15
10
5
0
0 3 6 9 12 15 18 21 24
Months since Randomization
T2DM/Placebo
T2DM/Dapa
No T2DM/Placebo
No T2DM/Dapa
Number at Risk
No T2DM/Dapagliflozin 1298 1281 1254 1235 1178 926 691 377 129
No T2DM/Placebo 1307 1286 1260 1245 1181 920 686 379 133
T2DM/Dapagliflozin 1075 1061 1042 1016 952 740 552 295 104
T2DM/Placebo 1064 1044 1019 986 911 718 535 286 102
No T2DM/Dapagliflozin
No T2DM/Placebo
T2DM/Dapagliflozin
T2DM/Placebo

FIG. 9D

FIG. 10A Effect of dapagliflozin on the primary endpoint in patients with and without diabetes and according to glycated haemoglobin level in patients without diabetes.




FIG. 10B Effect of dapagliflozin, compared with placebo on the prespecified primary and secondary composite outcomes, their components and all-cause mortality, according to diabetes status at baseline.






FIG. 11A

FIG. 11 Effect of dapagliflozin, compared with placebo, on laboratory measures, systolic blood pressure and weight, according to diabetes status




14085545_1 / 10

FIG. 11B




14085545_1 / 11

FIG. 11C




14085545_1 / 12

FIG. 11D



14085545_1 / 13

FIG. 11E



14085545_1 / 14

FIG. 12 Outcomes according to baseline flycated haemoglobin level (as a continuous variable)




FIG. 12A




FIG. 12C

FIG. 12B





FIG. 12D

14085545_1 / 15

Consistent symptom benefit irrespective of threshold on KCCQ-TSS, 8 months

Responder analysis **KCCQ-TSS Win Ratio = 1.18 (CI 1.11, 1.26), P<0.0001**

	Dapa 10 mg (N=2086)	Placebo (N=2062)	OR (95%CI)
Improvement			
5 or more points	1198 (57.4%)	1030 (50.0%)	1.15 (1.08, 1.23)
10 or more points	1124 (53.9%)	968 (46.9%)	1.15 (1.08, 1.22)
15 or more points	1120 (53.7%)	984 (47.7%)	1.14 (1.07, 1.22)



	Dapa 10 mg (N=2086)	Placebo (N=2062)	OR (95%CI)
Deterioration			
5 or more points	524 (25.1%)	682 (33.1%)	0.84 (0.78, 0.90)
10 or more points	385 (18.5%)	495 (24.0%)	0.85 (0.79, 0.92)




FIG. 13



Diabetes 0.73 (0.39-1.34)
No Diabetes 0.67 (0.30-1.49)
P for interaction = 0.87
Placebo
Diabetes (----)
Dapagliflozin
No Diabetes(——)
Placebo
Diabetes (----)
Dapagliflozin
No Diabetes (——)
Cumulative Percentage (%)
0
1
2
3
4
5
0
3
6
9
12
15
18
21
24
Months since Randomization
Number at Risk
Dapagliflozin Diabetes 1075 1042 1013 969 900 696 511 276 103
Dapagliflozin No Diabetes 1298 1253 1214 1173 1109 874 642 346 120
Placebo Diabetes 1064 1028 991 935 861 674 493 255 92
Placebo No Diabetes 1307 1249 1210 1183 1114 863 639 345 123

FIG. 14



Change in eGFR (per ml/min/1.73m)
0
-2
-4
-6
-8
014
60
120
240
360
480
600
720
Days from randomization
Placebo
Dapagliflozin
Day 14-720
Placebo -2.87 (95%CI -3.19 to -2.55)
Dapagliflozin -1.09 (95%CI -1.41 to -0.78)
Difference in slopes P <0.001
Day 0-14
Placebo -28.46 (95%CI -36.95 to -19.99)
Dapagliflozin -109.35 (95%CI -117.84 to -100.87)
Difference in slopes P <0.001

FIG. 15



Day 14-720
Placebo -3.56 (95%CI -4.06 to -3.06)
Dapagliflozin -1.29 (95%CI -1.78 to -0.80)
Difference in slopes P <0.001
Day 0-14
Placebo -26.00 (95%CI -38.70 to -13.31)
Dapagliflozin -122.26 (95%CI -134.82 to -109.69)
Difference in slopes P <0.001
Placebo
Dapa
Change in eGFR per ml/min/1.73m2
Days from randomization
No Diabetes at Baseline
Day 14-720
Placebo -3.11 (95%CI -3.42 to -2.80)
Dapagliflozin -2.05 (95%CI -2.36 to -1.75)
Difference in slopes P <0.001
Day 0-14
Placebo -30.47 (95%CI -41.85 to -19.08)
Dapagliflozin -98.61 (95%CI -110.09 to -87.12)
Difference in slopes P <0.001
Placebo
Dapa
Change in eGFR per ml/min/1.73m2
Days from randomization
Diabetes at Baseline

FIG. 16



Kaplan-Meier Plot of the Incidence of New-Onset Diabetes
Cumulative Percentage (%)
0
2.5
5
7.5
10
12.5
15
0
3
6
9
12
15
18
21
24
Months since Randomization
Number at Risk
Dapagliflozin 1298 1266 1233 1208 1147 895 666 366 123
Placebo 1307 1268 1225 1198 1127 874 642 358 125
Dapagliflozin
Placebo

FIG. 17




Fig. 18A




Fig. 18B